Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy
Public ClinicalTrials.gov record NCT02075255. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) to Reduce Oral Corticosteroid Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist and Chronic Oral Corticosteroid Therapy (ZONDA)
Study identification
- NCT ID
- NCT02075255
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 220 participants
Conditions and interventions
Conditions
Interventions
- Benralizumab Biological
- Placebo Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 27, 2014
- Primary completion
- Aug 7, 2016
- Completion
- Aug 7, 2016
- Last update posted
- Jun 7, 2018
2014 – 2016
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Los Angeles | California | 90025 | — |
| Research Site | Centennial | Colorado | 80112 | — |
| Research Site | Denver | Colorado | 80206 | — |
| Research Site | Hialeah | Florida | 33010 | — |
| Research Site | Hialeah | Florida | 33013 | — |
| Research Site | Miami | Florida | 33015 | — |
| Research Site | Orlando | Florida | 32825 | — |
| Research Site | Iowa City | Iowa | 52242 | — |
| Research Site | Fort Mitchell | Kentucky | 41017 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | The Bronx | New York | 10461 | — |
| Research Site | Durham | North Carolina | 27704 | — |
| Research Site | Winston-Salem | North Carolina | 27103 | — |
| Research Site | Cincinnati | Ohio | 45231 | — |
| Research Site | Middleburg Heights | Ohio | 44130 | — |
| Research Site | Oklahoma City | Oklahoma | 73112 | — |
| Research Site | Philadelphia | Pennsylvania | 19140 | — |
| Research Site | Pittsburgh | Pennsylvania | 15213 | — |
| Research Site | Mt. Pleasant | South Carolina | 29464 | — |
| Research Site | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 67 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02075255, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 7, 2018 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02075255 live on ClinicalTrials.gov.